University of Leicester (UoL) Research Governance Office
SOP S-1039 UoL
Version 3, October 2016

Case Report Form Production for Research Studies
Sponsored by the University of Leicester

OFFICE BASE
Research Governance Office
Research & Enterprise Division
University of Leicester
Fielding Johnson Building
University Road
Leicester
LE1 7RH

Effective Date: April 2017
1. INTRODUCTION

The purpose of this SOP is to standardise the approach for designing Case Report Forms (CRFs) for research sponsored by the University of Leicester (UoL).

The UoL sponsors a wide range of research ranging from simple qualitative studies to complex highly regulated Clinical Trials of Investigational Medicinal Products (CTIMPs) and it is recognised that the CRF requirements will vary accordingly. The type of CRF used needs to be proportionate to the risk associated with the study and this will be determined during the Sponsor Risk Assessment process. Where possible the services of a Clinical Trial Unit (CTU) should be used for CRF (and database) production, however, the principles of CRF design are the same irrespective of the complexity or size of the study.

2. SCOPE

This SOP applies to all research studies sponsored by the UoL.

3. DEFINITION

The data collection tool or CRF may be a paper CRF (pCRF) which can be a very simple paper document ranging from one page to a folder of pages. It may also be a computer application where the data are entered into an electronic case report form (eCRF), which is commonly in a web based portal system or, less frequently on a standalone computer/laptop. The type of CRF used will vary according to the requirements of each individual study. The Chief Investigator in collaboration with the Sponsor will need to decide which system is most suitable for each particular trial. More information on the specifications for eCRFs can be found in the Data Management SOP, SOP S-1036 UoL.

4. CRF DESIGN

CRF design must be guided by the requirements of the protocol and the planned statistical analysis of the trial data. This principle remains the same whether the CRF is in paper or electronic format. The CRF needs to be appropriately structured with each study visit clearly defined. A CRF template is available for use and includes all potentially required fields (Appendix 1). Guidance for CRF design is given in Appendix 2.

The following would be considered key elements for a CRF (some may not be applicable – this depends on the type of trial):

- Field for unambiguous subject identity code on each page
- Field for visit date on each page
- Field per visit for initials of person completing CRF
- Screening and baseline visit(s)
  - Subject demography
  - Disease characteristics of the subject
  - Medical and medication history and physical examination
  - Data used to assess eligibility (list of inclusion and exclusion criteria)
  - Confirmation of eligibility with a space for CI / PI signature to confirm eligibility (or medically qualified delegate)*
  - Initial data for the primary and secondary endpoints
- Subject randomisation
- Trial visits
  - During and post-treatment data for the primary and secondary endpoints

*: Where a medically qualified delegate is used, the appropriate title should follow e.g. Consultant, Consultant in Medicine.
o Data to assess compliance with the protocol and the (IMP) treatment regimen
o Exploratory or health outcome data not related to the main end-points
o Safety data

• Final visit (trial completion/withdrawal)
• Adverse events
• Concomitant medications and other interventions
• Serious adverse events forms
• Field for the signature indicating approval of the final data by the CI or PI

* For Clinical Trials of Investigational Medicinal Products (CTiMPs) where any eligibility are confirmed there must be evidence of who performed this confirmation to verify that the final decision to enter a subject into a trial was made by a medically qualified doctor. This must be reflected in the Delegation of Authority and Signature Log.

4.1 Timing

CRF design can be performed simultaneously with the development of the protocol or following finalisation of the protocol. Whichever approach is used, there should be a process in place for adequate version control during the drafting process and once the CRF is finalised. The CRF needs to be reviewed by the sponsor and finalised prior to the study site initiation visit.

4.2 Amendments to the CRF post-finalisation

Often, during a study a protocol amendment may be required and as a result, changes to the CRF (and database) may be necessary. It is expected that where this applies, amendments to the database and CRF are made during the approval process for amendments and the Sponsor informed. All changes must be version controlled.

5. CRF REVIEW AND APPROVAL

The CRF should be designed with detailed reference to the protocol capturing all, and only, the information required by it. Appropriate personnel, including the person who will be analysing the data, should review the CRF to ensure that:

a) the appropriate data are being collected and
b) that the data are consistent with the trial protocol.

Reviews must be retained and evidenced within the Trial Master File.

The CRF does not need to be a signed document, however, it is recommended that there is documented evidence of approval of the final version (and any amendments) by relevant personnel to ensure that it is fit to collect the data required so that the objectives of the study are met.

For CTIMP studies, Sponsor green light will not be given until the CRF is finalised.

6. CRF COMPLETION GUIDELINES

For large, complex or multi-centre trials it may be useful to compile a CRF completion guideline which would typically include advice on:

• Date format and partial dates
• Time format and unknown times
• Rounding conventions
• Trial – specific interpretation of data fields
• Entry requirements for concomitant medications (generic or branded names)
• Which forms to complete when
What to do in certain scenarios, for example when a subject withdraws from the trial  
- Missing/incomplete data  
- Completing SAEs and reporting SAEs  
- Repeat laboratory tests  
- Protocol and GCP non-compliances.

7. **SOURCE DATA**

All clinical Trial information should be recorded, handled and stored in a way that allows its accurate reporting, interpretation and verification and applies to all types of records, irrespective of the type of media used.

While the CRF is normally used for transcribing data from the source data, there may be circumstances where the CRF has data directly recorded onto it, meaning that at least part of the CRF is a source document. In these circumstances such data should be listed as source data in the trial protocol and Source Data Agreement (see Appendix 4 to SOP S-1007 UoL).

A copy of an original record (irrespective of the type of media used) should be certified to have the same information as the original.

8. **DATA RECORDING TOOLS FOR TRIAL SUBJECTS**

Occasionally data are entered by the trial subjects themselves (or their carers) into paper or electronic diaries/self-assessment questionnaires. Where this is the case it is recommended that diaries are designed to facilitate data collection by taking into account possible infirmities of the subjects, such as difficulty in writing or eyesight problems. The recorded data may have a high level of importance – for example, they may be an end-point for a trial recording pain or asthma symptoms. This will be identified at the risk assessment stage. Consideration must be given to the importance of the subject recorded data and appropriate control processes implemented to ensure the robustness of the data.

If paper diary data are to be entered into a database by a separate data management facility, the diaries must be checked to ensure there are no subject identifiers present prior to removal from the investigator site and a copy should be retained by the investigator.

9. **WORKSHEETS AND CRFS**

There are situations where trial-specific observations or tests are not performed routinely on site and therefore to avoid missing data use of a worksheet may be warranted. This may be particularly important for studies with high throughput and/or time-dependent data requirements such as vital signs in an intensive therapy unit setting. In these instances the worksheets should be version controlled to ensure they are updated in line with any amendments to the protocol (e.g. eligibility criteria, additional data points). When worksheets are used as source data they must be retained and filed with patient notes.

10. **RESPONSIBILITIES**

<table>
<thead>
<tr>
<th>Responsibility</th>
<th>Undertaken by</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sponsor/CI</td>
<td>Research Governance Manager or delegate &amp; CI</td>
</tr>
<tr>
<td>2</td>
<td>CI or delegate</td>
<td>CI or delegate</td>
</tr>
</tbody>
</table>
### Responsibility Undertaken by Activity

<table>
<thead>
<tr>
<th>Responsibility</th>
<th>Undertaken by</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Statistician (or other person analysing the data) and other relevant personnel</td>
<td>Statistician (or other person analysing the data) and other relevant personnel</td>
<td>Review the CRF to verify the appropriate data are being recorded and to ensure consistency with the protocol. Document and retain evidence of this review.</td>
</tr>
<tr>
<td>4 Chief Investigator</td>
<td>Chief Investigator or delegate</td>
<td>Ensure the accuracy, completeness, legibility and timeliness of the data recorded in the CRF.</td>
</tr>
<tr>
<td>5 Chief Investigator</td>
<td>Chief Investigator or delegate</td>
<td>In the event of a protocol amendment perform a review of the CRF and ensure appropriate changes are made and version controlled.</td>
</tr>
</tbody>
</table>

This table is used to track the development and approval of the document and any changes made on revised / reviewed versions:

### Development and approval Record for this document

**Author/Lead Officer:** Joanne Thompson  
**Job Title:** Medical Writer, Clear Clinical Research Ltd  
**Reviewed by:** Research Sponsorship Management and Operations Group  
**Approved by:** Professor Nigel Brunskill  
**Date Approved:** 10/04/2017

### Review Record

<table>
<thead>
<tr>
<th>Date</th>
<th>Issue Number</th>
<th>Reviewed By</th>
<th>Description Of Changes (If Any)</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2015</td>
<td>2</td>
<td>Diane Delahooke</td>
<td>Introduction of CRF template.</td>
</tr>
<tr>
<td>Oct 2016</td>
<td>3</td>
<td>Diane Delahooke</td>
<td>Change of logo and RGO address. Addition of need for CRF to be finalised before Sponsor green light given for CTIMP studies.</td>
</tr>
</tbody>
</table>

### Distribution Record

<table>
<thead>
<tr>
<th>Date</th>
<th>Name</th>
<th>Department</th>
<th>Received</th>
</tr>
</thead>
</table>